Robert Mannel to Erlotinib Hydrochloride
This is a "connection" page, showing publications Robert Mannel has written about Erlotinib Hydrochloride.
Connection Strength
0.082
-
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009 Jul; 19(5):929-33.
Score: 0.082
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.